Biotechnology

Pharming Group will report its Q3 2025 financial results and provide a business update on November 6th. Investors will focus on Ruconest® performance amid competitive HAE therapies and Pharming’s ability to maintain market share. The update will detail R&D pipeline progress, strategic initiatives including collaborations/acquisitions, and capital allocation. Analysts anticipate insights into revenue growth, expense management, and pipeline advancement’s impact on investor sentiment and future prospects. Guidance on full-year performance and strategic priorities will also be closely watched.

Spyre Therapeutics (SYRE) announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, projecting $275.0 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 2,229,729 shares. The offering is expected to close around October 15, 2025, pending customary conditions. Funds will support research and development of antibody therapies for IBD and other immune-mediated conditions. Jefferies, TD Securities, Leerink Partners, and Stifel acted as joint book-running managers.

Adicet Bio, Inc. announced an inducement award to a new employee joining in September 2025. The individual received a non-qualified stock option to purchase 9,800 shares at $0.81 per share, the closing price on the grant date. The options vest over four years with a one-year cliff, contingent upon continued employment. The award was granted under the 2022 Inducement Plan and approved by the independent compensation committee, adhering to Nasdaq Listing Rule 5635(c)(4). Adicet Bio focuses on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

Defence Therapeutics (DTCFF) appointed Dr. Amie Phinney to its Board of Directors. Dr. Phinney, previously a Strategy and Business Advisor, will now contribute to corporate governance and value creation as the company advances its drug-delivery platform. Defence granted her 100,000 stock options, exercisable at $0.75 per share. This appointment aims to enhance the company’s leadership and capitalize on Dr. Phinney’s pharma and biotech expertise, potentially impacting treatment landscapes.

Revive Therapeutics (RVVTF) is extending its private placement to raise up to $650,000 by issuing units at $0.021 each. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. Having already raised $60,900 in the first tranche, the remaining $589,000 will be used for working capital and settling trade payables. The securities are subject to a four-month and one-day hold period. While providing needed capital, the offering involves significant dilution potential for shareholders.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.

Innate Pharma announced its total outstanding shares and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and 6,434, plus 7,581 preferred shares. Total theoretical voting rights stood at 92,962,943, with 92,944,368 exercisable rights. This disclosure complies with French regulatory requirements.

SOHM, Inc. appointed Ravi Kapoor as an Independent Director. Kapoor brings over 30 years of experience in corporate law, M&A, and financial management. His expertise is expected to enhance SOHM’s strategic direction, corporate governance, and growth initiatives, particularly aligning with the company’s focus on generic drugs and gene-editing technologies.

Lipella Pharmaceuticals Inc. is delisted from the Nasdaq Capital Market due to rule violations regarding private placement transactions. The delisting, involving the issuance of convertible preferred stock and warrants, led to the suspension of trading. While disappointed, the company is exploring alternative markets, remains focused on its clinical development plans for LP-10 and LP-310, and is pressing forward with its mission to address unmet medical needs.

GRI Bio (NASDAQ: GRI), a San Diego-based biotech targeting iNKT cells for autoimmune therapies, will present its immunomodulatory platform at A.G.P.’s 2025 Healthcare Showcase on May 21 (2:40 PM ET) via live webcast. Dr. Marc Hertz, CEO, will outline advancements over traditional CAR-T approaches and highlight upcoming Phase II results for GRI-0621 (IPF/lupus pipelines) and its 500-compound library. The event attracts 500+ investors and historically correlates with 8% stock performance gains, offering critical visibility for the company’s early-inflammation intervention strategy. [99 words]